GlaxoSmithKline’s Relvar Ellipta showed better results in controlling asthma than other treatments, company representatives announced following Salford Lung Study (SLS) results.
“The Salford Lung Study Program is the first of its kind,” Professor Neil Barnes, global medical head, respiratory franchise at GlaxoSmithKline, said in a press release. “Through this unique study, we saw a meaningful impact on the daily lives of people managing asthma.”
With conclusions published in The Lancet and presented at the European Respiratory Society (ERS) International Congress in Milan, Italy, the study demonstrated that the product, called Breo Ellipta in the U.S., yielded measurable improvement when taken once daily over a 12-month period compared with other medicines.
Safety was also determined equivalent, with Ellipta’s incidence of significant side effects resulting in the same frequency as control medicines at 13 percent. Patients receiving the treatment also achieved higher life quality scores, less work and activity impairment and lower reliance on salbutamol inhalers, or rescue medication.
“Living with asthma can have a significant effect on people’s day to day life,” lead investigator Ashley Woodcock, professor and clinical director for respiratory medicine at University Hospital of South Manchester and University of Manchester, said. “Unfortunately, people with asthma often don’t realize improvements can be made to these parts of their lives. [Research is important] to help the medical community manage asthma in a way that has a positive impact for people living with this debilitating condition. We’re delighted the Lancet has published the results of what I believe to be a pioneering study.”